Veloxis Pharmaceuticals A/S, headquartered in Denmark (DK), is a prominent player in the biopharmaceutical industry, specialising in the development of innovative therapies for transplant patients. Founded in 2013, the company has made significant strides in enhancing patient outcomes through its unique formulations and targeted drug delivery systems. With a focus on immunosuppressive therapies, Veloxis is best known for its flagship product, Envarsus XR, which offers a once-daily dosing regimen that improves adherence and reduces side effects compared to traditional treatments. The company operates primarily in Europe and North America, positioning itself as a leader in the transplant market. Veloxis Pharmaceuticals has achieved notable milestones, including successful clinical trials and regulatory approvals, solidifying its reputation for excellence in patient care and commitment to advancing transplant medicine.
We don't have data for Veloxis Pharmaceuticals A/S, but we can show you information about their parent organization instead.
View parent company